Stockscreener 앱 받기
10.04
0.00%
0.00
전일 마감가:
$10.04
열려 있는:
$10.0004
하루 거래량:
4,423
Relative Volume:
1.03
시가총액:
$N/A
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.00%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$10.00
$10.04
1주일 범위
$10.00
$10.04
52주 변동 폭
$10.00
$10.05
Translational Development Acquisition Corp Stock (TDACU) Company Profile
명칭
Translational Development Acquisition Corp
전화
-
주소
-
TDACU을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TDACU
Translational Development Acquisition Corp
|
10.04 | 0 | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
6.92 | 2.00B | 3.13B | 50.80M | 555.00M | 0.1772 |
|
BZAI
Blaize Holdings Inc
|
7.56 | 792.89M | 0 | 0 | 0 | 0.00 |
|
AACT
Ares Acquisition Corporation Ii
|
11.00 | 687.50M | 0 | 16.92M | -1.35M | 0.29 |
|
ANNA
Aleanna Inc
|
11.50 | 466.44M | 0 | 0 | 0 | 0.00 |
|
ANSC
Agriculture Natural Solutions Acquisition Corp
|
10.51 | 453.24M | 0 | 1.30M | 0 | 0.0301 |
Translational Development Acquisition Corp 주식(TDACU)의 최신 뉴스
TDACU stock touches 52-week low at $10 amid market challenges - Investing.com
Special Purpose Acquisition Company (SPAC) News and Analysis - SPACInsider
TDACU stock touches 52-week low at $10.01 amid market shifts - Investing.com Nigeria
TDACU stock touches 52-week low at $10.01 amid market shifts By Investing.com - Investing.com South Africa
NextCure Initiates Phase 1 Study for B7-H4 ADC Therapy to Treat Multiple Cancers_ - Defense World
ICR, the Leading SPAC Communications and Advisory Firm, Publishes its Yearend 2024 SPAC Market Update & Outlook - Business Wire
Trident Acquisitions stock hits 52-week high at $10.04 - Investing.com India
Trident Acquisitions stock hits 52-week high at $10.04 By Investing.com - Investing.com UK
Translational Development Acquisition Corp. Announces Closing of $172.5 Million Initial Public Offering, Including Full Exercise of Underwriter's Over-Allotment Option - Finansavisen
Translational Development Acquisition Corp. Announces the Pricing of $150,000,000 Initial Public Offering - The Eastern Progress Online
Translational Development Acquisition Corp Launches $150M IPO on Nasdaq, Units to Trade as TDACU - StockTitan
Translational Development Acquisition Corp. (TDACU) Prices $150M IPO - SPACInsider
What’s next for the man charged with killing UnitedHealthcare’s CEO? - 69News WFMZ-TV
Italy's privacy watchdog fines OpenAI for ChatGPT's violations in collecting users personal data - 69News WFMZ-TV
For airports, background music no longer is an afterthought - 69News WFMZ-TV
The Fed expects to cut rates more slowly in 2025. What that could mean for mortgages, debt and more - 69News WFMZ-TV
Valink Therapeutics Appoints Biopharmaceutical Veteran Martin D. Williams as Chair of the Board of Directors and Names Scientific Advisory Board - Business Wire
(PDF) Translational Science: A Road Map for the Science of Reading - ResearchGate
Deal Watch: Dealmakers Brace for Impact of Presidential Election - Law.com
IPO NewsUS IPO Weekly Recap: Sizable tech and biotech IPOs are joined by a flurry of small names - Renaissance Capital
NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines - Business Wire
Bruker Completes Asset Acquisition of NanoString Business - Business Wire
Novartis Extends Its Reach in Radiopharmaceuticals With $1B Mariana Oncology Acquisition - MedCity News
NanoString Technologies to Be Acquired by Bruker Corporation - Business Wire
Initial Public Offering (IPO) News Live Feed - StockTitan
Novo Nordisk Expands Boston Area Research and Early Development - Genetic Engineering & Biotechnology News
Merck to Acquire Caraway Therapeutics, Inc. - Business Wire
Organoids Evolve from Academic Marvel to Industrial Tool - Genetic Engineering & Biotechnology News
Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases - PR Newswire
Locks on Translation Initiation May Restrain Cancer - Genetic Engineering & Biotechnology News
Offerings News Live Feed - StockTitan
NIH launches new initiative: Tackling Acquisition of Language in Kids (TALK) - NIDCD
NextRNA Therapeutics Strengthens Board of Directors with Appointment of Lori Friedman, PhD - Business Wire
FirstEnergy issues earnings report - 69News WFMZ-TV
Bollman Hat Company merges with GJ Littlewood & Son - 69News WFMZ-TV
ODDITY Invests $100M to Bring Pharma’s AI Based Molecule Discovery Technology to Beauty and Wellness. - Business Wire
Zura Bio Announces Appointment of Chief Scientific Officer - Business Wire
BMS Collaboration Paying Off for Exscientia - Genetic Engineering & Biotechnology News
Developing a metabolic clearance rate framework as a translational analysis approach for hyperpolarized - Nature.com
Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer - Business Wire
Cultural barriers hinder women’s growth in entrepreneurship - The Malaysian Reserve
Translation regulatory factor BZW1 regulates preimplantation embryo development and compaction by restricting global non-AUG Initiation - Nature.com
Gate Neurosciences Emerges from Stealth with a Portfolio of Next-Generation Therapies for Central Nervous System Diseases - Business Wire
Unlocking growth in SMEs: The driving forces of Malaysia’s economy - The Malaysian Reserve
Into Orbit: Satellite Bio Raises $110M toward Tissue Therapeutics - Genetic Engineering & Biotechnology News
Oak Hill Bio Appoints Tauhid Ali CEO - citybiz
Oak Hill Bio Appoints Tauhid Ali as First Chief Executive Officer - Business Wire
The Matrix Recellularized: Humacyte Manufactures Bioengineered Human Tissues at Commercial Scale - Genetic Engineering & Biotechnology News
EyeBio Raises $65M in Series A Funding to Develop New Generation of Eye Disease Therapies - Business Wire
Psychedelic Science Leader Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp. II - Business Wire
Third Rock Ventures Announces Promotion of David Kaufman, M.D., Ph.D., to Partner - Business Wire
Translational Development Acquisition Corp (TDACU) 재무 분석
Translational Development Acquisition Corp (TDACU)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.15%
0.02%
자본화:
|
볼륨(24시간):